<p>MicroCT scans of mouse femur and tibia; normal control (A), RM1(BM) tumour-bearing (B), RM1(BM) tumour-bearing treated with the 20 µg/kg ZOL regimen (C), RM1(BM) tumour-bearing treated with the 100 µg/kg ZOL regimen (D).</p
<p>(A) MRI tumor volume and ADC determined at day 21 post-treatment-initiation shows a retardation o...
*<p>p<0.05, <sup>**</sup>p<0.01, <sup>***</sup>p<0.001, <sup>****</sup>p<0.0001 vs OVXvehicle of the...
<p>There was no significant change in bone surface area (A) induced by the presence of a tumour or t...
<p>H&E stained sections of the femoral head at 40X (A, C, E and G) and 120X (B, D, F and H) magnific...
The bisphosphonate, zoledronic acid (ZOL), can inhibit osteoclasts leading to decreased osteoclastog...
BACKGROUND: The bisphosphonate, zoledronic acid (ZOL), can inhibit osteoclasts leading to decreased ...
Background: The bisphosphonate, zoledronic acid (ZOL), can inhibit osteoclasts leading to decreased ...
Purpose: To evaluate the efficacy of zoledronic acid (ZOL) against osteosarcoma (OS) growth, progres...
<p><b>A</b>. Representative longitudinal histological images of tibiae from NSG mice at the end stag...
<p>(A–C) Histomorphometry parameter and images perform on the femur. (A) Number of Osteoclast on Bon...
<p>FACS analysis showing the percentage of Gr-1+CD11b+cells in spleen of control, tumor-bearing mice...
<p>(A) Femur Bone Mineral Density (BMD). (B) Trabecular bone volume on tissue volume (BV/TV) of the ...
Multiple myeloma is characterized by the growth of plasma cells in the bone marrow and the developme...
Prompted by preliminary findings, this study was conducted to investigate the impact of zoledronic a...
Prompted by preliminary findings, this study was conducted to investigate the impact of zoledronic a...
<p>(A) MRI tumor volume and ADC determined at day 21 post-treatment-initiation shows a retardation o...
*<p>p<0.05, <sup>**</sup>p<0.01, <sup>***</sup>p<0.001, <sup>****</sup>p<0.0001 vs OVXvehicle of the...
<p>There was no significant change in bone surface area (A) induced by the presence of a tumour or t...
<p>H&E stained sections of the femoral head at 40X (A, C, E and G) and 120X (B, D, F and H) magnific...
The bisphosphonate, zoledronic acid (ZOL), can inhibit osteoclasts leading to decreased osteoclastog...
BACKGROUND: The bisphosphonate, zoledronic acid (ZOL), can inhibit osteoclasts leading to decreased ...
Background: The bisphosphonate, zoledronic acid (ZOL), can inhibit osteoclasts leading to decreased ...
Purpose: To evaluate the efficacy of zoledronic acid (ZOL) against osteosarcoma (OS) growth, progres...
<p><b>A</b>. Representative longitudinal histological images of tibiae from NSG mice at the end stag...
<p>(A–C) Histomorphometry parameter and images perform on the femur. (A) Number of Osteoclast on Bon...
<p>FACS analysis showing the percentage of Gr-1+CD11b+cells in spleen of control, tumor-bearing mice...
<p>(A) Femur Bone Mineral Density (BMD). (B) Trabecular bone volume on tissue volume (BV/TV) of the ...
Multiple myeloma is characterized by the growth of plasma cells in the bone marrow and the developme...
Prompted by preliminary findings, this study was conducted to investigate the impact of zoledronic a...
Prompted by preliminary findings, this study was conducted to investigate the impact of zoledronic a...
<p>(A) MRI tumor volume and ADC determined at day 21 post-treatment-initiation shows a retardation o...
*<p>p<0.05, <sup>**</sup>p<0.01, <sup>***</sup>p<0.001, <sup>****</sup>p<0.0001 vs OVXvehicle of the...
<p>There was no significant change in bone surface area (A) induced by the presence of a tumour or t...
DOI
Add to ORKG